BioScout2018-05-23T10:03:13+00:00

Ion mobility spectrometer

BioScout

Medical Diagnosis via Breath Analysis
Ion Mobility Spectrometer BioScout

BioScout offers you the possibility to identify over 600 metabolites stored in our database. Studies have shown that BioScout is able to detect lung cancer, bacterial infections, COPD grades and much more.

  • Perl, T., Vautz, W., Nolte, J., Baumbach, J. I. & Quintel, M. Ion mobility spectrometry of human pathologic bacteria-metabolic profiling by volatile organic compounds. Infection 37, 24-24 (2009).
  • Perl, T., Veldhoen, S., Vautz, W. & Baumbach, J. I. Fast analysis of volatile metabolites by ion mobility spectrometry for characterization of bacteria. International Journal of Medical Microbiology 298, 17-17 (2008).
  • Baumbach, J. I. & Westhoff, M. Ion mobility spectrometry to detect lung cancer and airway infections. Spectroscopy Europe 18, 22-27 (2006).
  • Westhoff, M., Freitag, L., Ruzsanyi, V. & Baumbach, J. I. Bacterial differentiation by ion mobility spectrometry: First results of a pilot study. Chest 128, 375S-375S (2005).
  • Westhoff, M., Litterst, P., Freitag, L., Urfer, W., Bader, S. & Baumbach, J. I. Ion mobility spectrometry for the detection of volatile organic compounds in exhaled breath of patients with lung cancer: results of a pilot study. Thorax 64, 744-748, doi:10.1136/thx.2008.099465 (2009).
  • Baumbach, J. I. & Westhoff, M. Ion mobility spectrometry to detect lung cancer and airway infections. Spectroscopy Europe 18, 22-27 (2006).
  • Westhoff, M., Litterst, P., Maddula, S., Bödecker, B., Rahmann, S., Davies, A. N. & Baumbach, J. I. Differentiation of chronic obstructive pulmonary disease (COPD) including lung cancer from healthy control group by breath analysis using ion mobility spectrometry Int. J. Ion Mobility Spectrom. 13, 131-139 (2010).

Bacteria

Metabolites of bacteria and fungi

In an in vitro study IMS-chromatograms of different bacteria (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus agalactiae, Haemophilus influenzae, Klebsiella pneumoniae, Escherichia coli, Serratia marcescens, Pseudomonas aeruginosa, Enterobacter cloacae) and a fungus, Candida albicans, were obtained. The selected bacteria and Candida albicans could be defined and distinguished by different metabolites.

Bronchial Carcinoma

Differentiation Bronchial Carcinoma / Healthy

Breath analysis by IMS can detect a discriminating combination of VOCs in patients with lung cancer. By pattern recognition without the need for chemical analysis of the underlying VOCs, IMS has the potential to facilitate lung cancer diagnosis.

COPD

Metabolites related to COPD

Within a clinical study the exhaled breath of persons suffering with COPD (with and without lung cancer) and healthy volunteers was investigated using an Ion Mobility Spectrometer coupled to a Multi-Capillary Column without any pre-separation or pre-enrichment. A single analyte was able to separate the two groups of healthy persons and those suffering from COPD with and without lung cancer. The sensitivity obtained was 60%, the specificity 91%, the positive predictive value 95%. The peak was characterised as cyclohexanone (CAS 108-94-1). Thus, a concentration of cyclohexanone above the threshold could be seen as an indicator for COPD. The identity of the peak used for separation of the two groups mustbe validated with a greater population and external standards. Additional studies with a higher population and parallel measurements using GC/MSD will support the identification further.

Medication Control

Time series of metabolites related to pharmaceuticals

Metabolites in human breath were found relatable to pharmaceuticals. Time series are obtained by an investigation of single analytes directly.

Tumor Type

Tumor metabolites

Ion mobility spectrometry coupled to a multi capillary column (MCC/IMS) is currently evaluated for the analysis of exhaled breath to diagnose lung cancer. The origin of specific volatile organic compounds (VOC) detected in patients with non-small-cell lung cancer (NSCLC) still remains unknown.

We wondered whether there are different VOCs in bronchi close to the tumour and the lung of a cancer patient in general.

10 patients with histologically proven peripheral NSCLC were included in the study. During flexible bronchoscopy a catheter connected to an MCC/IMS was introduced through the working channel of the bronchoscope. Gas samples were aspirated from the tumour bearing side and the contralateral lung.

There were no adverse events. In the measured data set 61 common peaks could be detected. Four peak intensities were significantly different between the tumour bearing site and the unaffected side lung. Among these peaks, three peaks were significantly higher and one was lower on the tumour site. Two peaks showed a difference between both lungs only for adenocarcinoma and one particularly in patients with squamous cell and undifferentiated NSCLC.

Some VOCs are present in a different concentration in the air near by a NSCLC than in a distance of the tumour. Therefore these VOCs may reflect metabolic products of the tumour.

Contact

If you have any questions about this topic or want more information,
just contact our sales and service team.

+49 (0) 9771 6222 0

Ganshorn verwendet Cookies, um die Webseite optimal gestalten und fortlaufend verbessern zu können. Durch die weitere Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Weitere Informationen. Ok